(Q44614812)

English

The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status

scientific article published in October 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

0 references

vitamin deficiency

0 references

vitamin D deficiency

0 references

Klinefelter's syndrome

1 reference

based on heuristic

inferred from title

object named as

Václav Hána

3

0 references

Jan J. Štěpán

object named as

Jan J Stepan

1

0 references

author name string

Peter Burckhardt

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

589-596

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

The diagnosis of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone density and risk of hip fracture in men and women: cross sectional analysis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the registration of drugs intended for use in the treatment of male osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of male osteoporosis: report of the UK Consensus Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate for the Treatment of Osteoporosis in Men

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The psychoeducational profile of boys with Klinefelter syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute effects of calcium infusion on hydroxyproline

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Syndrome Characterized by Gynecomastia, Aspermatogenesis without A-Leydigism, and Increased Excretion of Follicle-Stimulating Hormone1

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2803%2900205-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S8756-3282(03)00205-9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44614812&oldid=2029377499"